精彩内容近日,成都市公共卫生临床医疗中心公告称,拟引进4款新药以满足临床用药需求,均为独家1类创新药(含剂型独家,下同);从治疗大类上看,以抗肿瘤和免疫调节剂(化+生)和神经系统药物(化+生)为主,其2025H1在中国公立医疗机构终端销售额分别超1200亿元和520亿元。拟进院新药包含2款化药和2款生物药;从剂型上看,注射剂和胶囊剂分别占3个和1个席位;按治疗大类统计,抗肿瘤和免疫调节剂以3个产品...
Source Link精彩内容近日,成都市公共卫生临床医疗中心公告称,拟引进4款新药以满足临床用药需求,均为独家1类创新药(含剂型独家,下同);从治疗大类上看,以抗肿瘤和免疫调节剂(化+生)和神经系统药物(化+生)为主,其2025H1在中国公立医疗机构终端销售额分别超1200亿元和520亿元。拟进院新药包含2款化药和2款生物药;从剂型上看,注射剂和胶囊剂分别占3个和1个席位;按治疗大类统计,抗肿瘤和免疫调节剂以3个产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.